Chronic Lymphoproliferative Disorder of NK-Cells

Chronic Lymphoproliferative Disorder of NK-Cells — Trials · CancerIndex

Clinical trials

Registered studies

7 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06530576	Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia	recruiting	Phase 2	48	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Nov 18, 2025	clinicaltrials
NCT06716658	JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas	recruiting	Phase 2	48	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Nov 18, 2025	clinicaltrials
NCT06530550	PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas	recruiting	Phase 2	51	Institute of Hematology & Blood Diseases Hospital, ChinaOTHER	1	Aug 12, 2025	clinicaltrials
NCT04453345	TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL	unknown	Phase 2 / Phase 3	42	Institute of Hematology & Blood Diseases Hospital, China

Data updated 23 days agoSource updated Nov 18, 2025source: clinicaltrials